ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1900

Urate Lowering Therapy in the Treatment of Gout: A Multicenter, Randomized, Double-blind Comparison of Allopurinol and Febuxostat Using a Treat-to-Target Strategy

James O'Dell1, Tuhina Neogi2, Michael Pillinger3, Paul Palevsky4, Jeff Newcomb1, Mary Brophy5, Hongsheng Wu5, Annie Davis-Karim6, Ryan Ferguson5, David Pittman6, Robert Terkeltaub7, Amy Cannella1, Bryant England1, Lindsay Helget1, Ted Mikuls1 and Tomas Taylor8, 1University of Nebraska Medical Center, Omaha, NE, 2Boston University School of Medicine, Boston, MA, 3New York University Grossman School of Medicine, New York,, NY, 4Pittsburgh University, Pittsburgh, PA, 5Boston VA, Boston, MA, 6Albuquerque VA, Albuquerque, NM, 7VA/UCSD, San Diego, CA, 8White River Junction VA, White River Junction, VT

Meeting: ACR Convergence 2021

Keywords: Allopurinol, clinical trial, Febuxostat, gout, VA

  • Tweet
  • Email
  • Print
Session Information

Date: Tuesday, November 9, 2021

Title: Abstracts: Metabolic & Crystal Arthropathies – Basic & Clinical Science (1897–1900)

Session Type: Abstract Session

Session Time: 11:15AM-11:30AM

Background/Purpose: Urate lowering therapy (ULT) is a cornerstone treatment in the management of gout. A paucity of data exists about the relative efficacy and safety of the two major oral ULTs, allopurinol and febuxostat, when administered as part of a treat-to-target approach as recommended by ACR and EULAR. Evidence regarding the comparative efficacy and safety of these agents is particularly needed in the context of chronic kidney disease (CKD), a common comorbid condition among gout patients. This multicenter, randomized, double-blind, non-inferiority trial was designed to examine the comparative efficacy and safety of these ULTs in gout management.

Methods: Patients with gout and a serum urate (SU) concentration ≥ 6.8 mg/dl were randomized 1:1 between 2017-2019 to receive appropriately titrated allopurinol or febuxostat in this non-inferiority 72-week trial. Patients with persistent hyperuricemia, despite treatment with allopurinol (≤ 300 mg/dl), were eligible and the protocol specified that ≥ 1/3 would have CKD stage 3. The trial had 3 phases: 1) ULT titration (weeks 0-24), 2) Maintenance (weeks 25-48), and 3) Observation, with continued stable ULT (weeks 49-72). Allopurinol and febuxostat were initiated in daily doses of 100 mg and 40 mg with maximum titration to 800 mg and 120 mg (reduced to 80 mg in 2019 per FDA’s request), respectively. Patients received anti-inflammatory prophylaxis chosen by site investigator according to 2012 ACR guidelines until the beginning of phase 3. The primary endpoint was the proportion of patients experiencing ≥ 1 flare during phase 3 with a pre-specified margin of < 8% difference indicative of non-inferiority. Secondary endpoints included: efficacy/tolerability in CKD stage 3, proportion achieving SU < 6 mg/dl at the end of phase 2, and serious adverse events (SAE).

Results: : Characteristics of the 940 patients with gout (n=21 sites) receiving at least 1 dose of study medication are shown in Table 1. Overall, 20% withdrew prior to completion with similar proportions by treatment arm. During phase 3, 35% of patients treated with allopurinol had ≥ 1 flare compared to 42% of participants treated with febuxostat (p < 0.001 for non-inferiority) (Table 2). Overall, 80% of patients achieved SU < 6.0 mg/dl (92% achieved SU < 6.8 mg/dl) during phase 2 with no difference according to ULT treatment. Likewise, there were no treatment differences in SAEs (including percent of patients with cardiovascular events) in those with or without CKD. Additional secondary outcomes are shown in Table 2.

Conclusion: This large, randomized double-blind trial demonstrates that allopurinol, when dosed appropriately as part of a treat-to-target strategy, is non-inferior to febuxostat in the treatment of gout. Both ULTs were highly efficacious in this context with 80% of patients achieving and maintaining SU goals after 1 year and more than 90% achieving SU < 6.8 mg/dl. There was no evidence of increased cardiovascular toxicity with febuxostat compared to allopurinol. Moreover, the comparative efficacy and safety of these two agents extended to patients with CKD stage 3, highly relevant as nearly one in every two gout patients suffers from renal insufficiency.


Disclosures: J. O'Dell, None; T. Neogi, Pfizer/Lilly, 2, Regeneron, 2, Novartis, 2; M. Pillinger, Horizon Therapeutics, 1, 5, Hikma Pharmaceuticals, 5; P. Palevsky, None; J. Newcomb, None; M. Brophy, None; H. Wu, None; A. Davis-Karim, None; R. Ferguson, None; D. Pittman, None; R. Terkeltaub, SOBI, 2, Selecta, 2, Allena, 2, Horizon, 2, Astra-Zeneca, 2, Astra-Zeneca, 5; A. Cannella, None; B. England, Boehringer-Ingelheim, 2; L. Helget, None; T. Mikuls, Gilead Sciences, 2, Horizon, 2, 5, Pfizer Inc, 2, Sanofi, 2, Bristol-Myers Squibb, 2; T. Taylor, None.

To cite this abstract in AMA style:

O'Dell J, Neogi T, Pillinger M, Palevsky P, Newcomb J, Brophy M, Wu H, Davis-Karim A, Ferguson R, Pittman D, Terkeltaub R, Cannella A, England B, Helget L, Mikuls T, Taylor T. Urate Lowering Therapy in the Treatment of Gout: A Multicenter, Randomized, Double-blind Comparison of Allopurinol and Febuxostat Using a Treat-to-Target Strategy [abstract]. Arthritis Rheumatol. 2021; 73 (suppl 9). https://acrabstracts.org/abstract/urate-lowering-therapy-in-the-treatment-of-gout-a-multicenter-randomized-double-blind-comparison-of-allopurinol-and-febuxostat-using-a-treat-to-target-strategy/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2021

ACR Meeting Abstracts - https://acrabstracts.org/abstract/urate-lowering-therapy-in-the-treatment-of-gout-a-multicenter-randomized-double-blind-comparison-of-allopurinol-and-febuxostat-using-a-treat-to-target-strategy/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology